ArticleThe Journal of infectious diseases2019
Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial.BMJ open · 2021Trial
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.Human vaccines & immunotherapeutics · 2026Article
- The Long-Term Effect of 2 and 3 Doses of Bivalent HPV Vaccination Against HPV Infections: A Comparison Between 2 Observational Cohort Studies.The Journal of infectious diseases · 2026Observational
- Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage.International journal of cancer · 2026Article
- Protective Human Papillomavirus Type 16/18 Vaccine-Induced Neutralizing Antibody Levels Remain Elusive.Open forum infectious diseases · 2026Article
- Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands.BMC medicine · 2025Article
- Changes in Genital Human Papillomavirus (HPV) Prevalence During 12 Years of Girls-Only Bivalent HPV Vaccination: Results From a Biennial Repeated Cross-sectional Study.The Journal of infectious diseases · 2025Article
- Viral and immune dynamics of genital human papillomavirus infections in young women with high temporal resolution.PLoS biology · 2025Observational
- Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccination.Journal of the National Cancer Institute. Monographs · 2024Article
- Observational
- HPV specificity and multiple infections and association with cervical cytology in Chongqing, China: a cross-sectional study.BMC infectious diseases · 2024Article
- Human papillomavirus genotype distribution patterns in Zimbabwe; is the bivalent vaccine sufficient?Intervirology · 2024Review
- Comparative genomics of Brucella abortus and Brucella melitensis unravels the gene sharing, virulence factors and SNP diversity among the standard, vaccine and field strains.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.Infectious diseases (London, England) · 2024Article
- Ability of epidemiological studies to monitor HPV post-vaccination dynamics: a simulation study.Epidemiology and infection · 2023Article
- The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study.Human vaccines & immunotherapeutics · 2022Article
- Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule.The Journal of infectious diseases · 2022Article
- Prevalence and distribution of human papillomavirus (HPV) in Luoyang city of Henan province during 2015-2021 and the genetic variability of HPV16 and 52.Virology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.